Reduced β-catenin and peroxisome proliferator-activated receptor-γ expression levels are associated with colorectal cancer metastatic progression: correlation with tumor-associated macrophages, cyclooxygenase 2, and patient outcome

Human Pathology

Volumn 40, Issue 5, 2009, Pages 714-725

  Pancione, Massimo ^a   Forte, Nicola ^b   Sabatino, Lina ^a   Tomaselli, Eugenio ^b   Parente, Domenico ^b   Febbraro, Antonio ^b   Colantuoni, Vittorio ^a  

^a UNIVERSITY OF SANNIO   (Italy)

^b FATEBENEFRATELLI HOSPITAL   (Italy)

Author keywords

Catenin; Colorectal cancer; Metastases; Peroxisome proliferator activated receptor; Prognosis

Indexed keywords

BETA CATENIN; CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL RATE; SURVIVAL TIME; TUMOR ASSOCIATED LEUKOCYTE; WESTERN BLOTTING;

ADENOCARCINOMA; AGED; BETA CATENIN; BLOTTING, WESTERN; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; MACROPHAGES; MALE; NEOPLASM METASTASIS; NEOPLASM STAGING; NF-KAPPA B; PPAR GAMMA; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 64049092259     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2008.08.019     Document Type: Article

References (36)

1. Potter J.D. Colorectal cancer. Molecules and populations. J Natl Cancer Inst 91 (1999) 916-932
2. Narayan S., and Roy D. Role of APC and DNA mismatch repair genes in the development of colorectal cancers. Mol Cancer 2 (2003) 41-55
3. de la Chapelle A. Genetic predisposition to colorectal cancer. Nat Rev Cancer 4 (2004) 769-780
4. Feezor R.J., Copeland E.M., and Hochwald S.N. Significance of micrometastases in colorectal cancer. Ann Surg Oncol 9 (2002) 944-953
5. Kinzler K.W., and Vogelstein B. Lessons from hereditary colorectal cancer. Cell 87 (1996) 159-170
6. Peifer M., and Polakis P. Wnt signaling in oncogenesis and embryogenesis. A look outside the nucleus. Science 287 (2000) 1606-1609
7. Korinek V., Barker N., Morin P.J., et al. Constitutive transcriptional activation by a β-catenin-Tcf complex in APC-/- colon carcinoma. Science 275 (1997) 1784-1787
8. Hemminichi A., Peltomaki P., Mecklin J.P., et al. Loss of the wild type MLH1 gene is a feature of hereditary nonpolyposis colorectal cancer. Nat Genet 8 (1994) 405-410
9. Sjöblom T., Jones S., Wood L.D., et al. The consensus coding sequences of human breast and colorectal cancers. Science 314 (2006) 268-274
10. Balkwill F., and Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 357 (2001) 539-545
11. Greten F., Eckmann L., Greten T., et al. IKKβ links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118 (2004) 285-296
12. Pikarsky E., Porat R.M., Stein I., et al. NF-kB functions as a tumour promoter in inflammation-associated cancer. Nature 431 (2004) 461-466
13. Oshima M., Dinchuk J., Kargman S.L., et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87 (1996) 803-809
14. Husain S.S., Szabo I.L., and Tarnawski A.S. NSAID inhibition of GI cancer growth: clinical implications and molecular mechanisms of action. Am J Gastroenterol 97 (2002) 542-553
15. Francis G.A., Fayard E., Picard F., and Auwerx J. Nuclear receptor and the control of metabolism. J Annu Rev Physiol 65 (2003) 261-271
16. Feige J.N., Gelman L., Michalik L., Desvergne B., and Wahli W. From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Prog Lipid Res 45 (2006) 120-159
17. Wang C.G., Fu M.F., D'Amico M., et al. Inhibition of cellular proliferation through Ikappa B kinase independent and peroxisome proliferator-activated receptor γ dependent repression of cyclin D1. Mol Cell Biol 21 (2001) 3057-3070
18. Motomura W., Okumura T., Takahaski N., Obara T., and Kohgo Y. Activation of peroxisome proliferator-activated receptor γ by troglitazone inhibits cell growth through the increase of p27(Kip 21) in human pancreatic carcinoma cells. Cancer Res 60 (2000) 5558-5564
19. Lefebvre A.M., Chen I., Desreumaux P., et al. Activation of the peroxisome proliferator-activated receptor γ promotes the development of colon tumors in C57BL/6J-APCMin/1 mice. Nat Med 4 (1998) 1053-1057
20. Sabatino L., Casamassimi A., Peluso G., et al. A novel peroxisome proliferator-activated receptor γ isoform with dominant negative activity generated by alternative splicing. J Biol Chem 280 (2005) 26517-26525
21. Seitz C.S., Lin Q., Deng H., and Khavari P.A. Alterations in NF-kB function in transgenic epithelial tissue demonstrate a growth inhibitory role for NF-kB. Proc Natl Acad Sci U S A 95 (1998) 2307-2312
22. Bommer G.T., and Fearon E.R. Role of c-Myc in Apc mutant intestinal phenotype: case closed or time for a new beginning?. Cancer Cell 11 (2007) 391-394
23. Thyssen G., Li T.H., Lehmann L., Zhuo M., Sharma M., and Sun Z. LZTS2 is a novel β-catenin-interacting protein and regulates the nuclear export of β-catenin. Mol Cell Biol 26 (2006) 8857-8867
24. Ebert M.P., Yu J., Hoffmann J., et al. Loss of β-catenin expression in metastatic gastric cancer. J Clin Oncol 21 (2003) 1708-1714
25. Kudo Y., Kitajima S., Ogawa I., et al. Invasion and metastasis of oral cancer cells require methylation of E-cadherin and/or degradation of membranous β-catenin. Clin Cancer Res 10 (2004) 5455-5463
26. Sarraf P., Mueller E., Smith W.M., et al. Loss-of-function mutations in PPARγ associated with human colon cancer. Mol Cell 3 (1999) 799-804
27. Michalik L., Desvergne B., and Wahli W. Peroxisome-proliferator-activated receptors and cancers: complex stories. Nat Rev Cancer 4 (2004) 61-70
28. DuBois R.N., Gupta R., Brockman J., Reddy B.S., Krakow S.L., and Lazar M.A. The nuclear eicosanoid receptor, PPARγ, is aberrantly expressed in colonic cancers. Carcinogenesis 19 (1998) 49-53
29. Burgermeister E., and Seger R. MAPK kinases as nucleo-cytoplasmic shuttles for PPARγ. Cell Cycle 6 (2007) 1539-1548
30. Yu J., Qiao L., Zimmerman L., et al. Troglitazone inhibits tumor growth in hepatocellular carcinoma in vitro and in vivo. Hepatology 43 (2006) 134-143
31. Jansson E.A., Are A., Greicius G., et al. The Wnt/β-catenin signaling pathway targets PPARγ activity in colon cancer cells. Proc Natl Acad Sci U S A 102 (2005) 1460-1465
32. Pascual G., Fong A.L., Ogawa S., et al. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPARγ. Nature 437 (2005) 759-763
33. Karin M. Nuclear factor-kB in cancer development and progression. Nature 441 (2006) 431-436
34. Shih J.Y., Yuan A., Chen J.J.W., and Yang P.C. Tumor-associated macrophage. Its role in cancer invasion and metastasis. J Cancer Mol 2 (2006) 101-106
35. Takada I., Mihara M., Suzawa M., et al. A histone lysine methyltransferase activated by non-canonical Wnt signalling suppresses PPARγ transactivation. Nat Cell Biol 9 (2007) 1273-1285
36. Pukrop T., and Binder C. The complex pathway of Wnt 5a in cancer progression. J Mol Med 86 (2008) 259-266